

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|--------------------------|--|--|-------------------------------------|---|
| Neurology | | | | |
| Psychosis; schizophrenia | Dopamine D3 receptor; serotonin (5-HT _{1A}) receptor; serotonin (5-HT _{2A}) receptor | <p>Mouse studies have identified new trifunctional arylpiperazines that could be useful as antipsychotics. The series of arylpiperazine analogs antagonized dopamine D3 and 5-HT_{2A} receptors and partially agonized the 5-HT_{1A} receptor. In mouse models of psychosis-related hyperactivity, several analogs decreased hyperactive behavior compared with vehicle without inducing cataplexy or tremors. Next steps include optimizing the pharmacokinetic properties of the molecules and identifying a lead candidate.</p> <p>SciBX 7(45); doi:10.1038/scibx.2014.1325 Published online Nov. 20, 2014</p> | Patented; unavailable for licensing | <p>Brindisi, M. <i>et al. J. Med. Chem.</i>; published online Oct. 24, 2014; doi:10.1021/jm501119j</p> <p>Contact: Giuseppe Campiani, Siena University, Siena, Italy e-mail: campiani@unisi.it</p> <p>Contact: Stefania Butini, same affiliation as above e-mail: butini3@unisi.it</p> |